Alligator Bioscience Secures USPTO Patent for Tetravalent Bispecific Antibody Platform
核心洞察
Alligator Bioscience (搜索) received USPTO patent protection for its proprietary tetravalent bispecific antibody format capable of dual antigen binding.
The patent covers versatile antibody architecture designed for stable assembly of bispecific antibodies targeting immune modulators and tumor-associated antigens.
The platform underpins multiple research programs and gained external validation through the September 2025 RUBY™ antibody format evaluation agreement.
Alligator Bioscience (搜索) announced on March 10, 2026, that the United States Patent and Trademark Office (USPTO) has granted a patent covering the company's proprietary bispecific antibody format. The Swedish clinical-stage biotechnology company received protection for the structural design of tetravalent bispecific antibodies capable of dual antigen binding, strengthening its intellectual property portfolio in the competitive immuno-oncology space.
Patent Coverage and Platform Design
The granted patent protects a versatile antibody architecture designed to enable stable and efficient assembly of bispecific antibodies. The platform encompasses configurations targeting immune modulators and tumor-associated antigens, positioning it to support the development of next-generation immunotherapies across a range of oncology indications and combination strategies.
The bispecific antibody format represents a key component of Alligator's research platform, underpinning multiple programs within the company's pipeline. The technology has already demonstrated external validation, as evidenced by Alligator's September 2025 evaluation and option agreement covering the RUBY™ antibody format, which highlighted commercial and strategic interest in the company's antibody engineering capabilities.
Strategic Value and Commercial Potential
"This patent grant strengthens the intellectual property foundation around our bispecific antibody platform and highlights the value of our technology beyond mitazalimab," said Søren Bregenholt, CEO of Alligator Bioscience (搜索). The patent supports the company's strategy to build long-term value through innovative antibody formats, both within its own pipeline and through partnerships, as exemplified by the RUBY™ agreement.
Company Background and Pipeline
Alligator Bioscience (搜索) focuses on developing tumor-directed immuno-oncology antibody drugs, with particular emphasis on the CD40 (搜索) receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, offering significant potential benefits for cancer (搜索) patients across multiple cancer types.
The company's lead drug candidate mitazalimab is currently ready for Phase 3 development and has previously presented unprecedented survival data at 30-months follow-up in first-line metastatic pancreatic cancer (搜索) patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm under the ticker ATORX and is headquartered in Lund, Sweden.